XML 51 R34.htm IDEA: XBRL DOCUMENT v3.21.2

Note 8 - Collaborative and Other Research and Development Contracts (Details Textual) - USD ($) $ in Thousands						1 Months Ended				3 Months Ended		9 Months Ended		12 Months Ended	70 Months Ended
	Sep. 03, 2020	Mar. 04, 2020	Nov. 05, 2019	Sep. 06, 2018	Jun. 16, 2015	Aug. 31, 2021	Aug. 31, 2020	Jun. 30, 2006	Jun. 30, 2000	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2019	Mar. 31, 2021	Mar. 31, 2015	Feb. 28, 2006
Proceeds from Collaborators												$ 6,918
Revenue from Contract with Customer, Including Assessed Tax										$ 40,994	$ 6,102	110,012	$ 13,796
Arbitration Proceedings of SUL Agreement [Member]
Litigation Settlement, Amount Awarded from Other Party		$ 5,000
Arbitration Proceedings of SUL Agreement [Member] | Other Income [Member]
Gain (Loss) Related to Litigation Settlement, Total													8,893
Arbitration Proceedings of SUL Agreement [Member] | Selling, General and Administrative Expenses [Member]
Legal Fees													$ 5,026
US Department of Health and Human Services [Member]
Collaborative Agreement Contract Value				$ 34,660
Contract Term (Year)				5 years
Proceeds from Collaborators	$ 6,932
Torii Pharmaceutical Co. [Member]
Upfront Payments Receivable Amount			$ 22,000
Potential Milestone Payments Receivable if Regulatory Approval Before December 31, 2021			$ 15,000
Maximum Customary Reduction on Royalty Rate			50.00%
Royalty Payments Receivable, Expiration Term From First Commercial (Year)			10 years
Revenue from Contract with Customer, Including Assessed Tax												1,617		$ 20,101
Torii Pharmaceutical Co. [Member] | Minimum [Member]
Royalty Rate if Maintains Sakigake Designation			20.00%
Torii Pharmaceutical Co. [Member] | Maximum [Member]
Royalty Rate if Maintains Sakigake Designation			40.00%
CSL Limited [Member
Proceeds from License Fees Received					$ 33,740
Milestone Payment Received															$ 12,000
Base Contract [Member]
Government Contract Receivable																$ 16,265
Additional Development Options [Member]
Government Contract Receivable																22,855
ASPRBARDA Contract [Member]
Government Contract Receivable																$ 39,120
Proceeds from awards for Research and Development Contracts												20,574
Green Cross Corporation [Member]
Proceeds from License Fees Received								$ 250
Mundipharma [Member]
Potential Milestone Payments Receivable																	$ 15,000
AECOM and IRL [Member]
Milestone Payment Minimum									$ 1,400
Milestone Payment Maximum									4,000
Annual License Fee Minimum									150
Annual License Fee Maximum									$ 500
National Institute of Allergy and Infectious Diseases [Member]
Expected Receivable From Awards for Research and Development Contracts						$ 45,931						$ 47,315
Collaborative Agreement Contract, Covenant, Maximum Amount of Funding							$ 43,908
Collaborative Agreement Contract Value							$ 6,326
UAB [Member]
Period of Agreement (Year)												25 years
Renewable Period of Agreement (Year)												5 years

X

- Definition

Represents annual maximum license fee.

+ References

No definition available.

+ Details

Name:	bcrx_AnnualLicenseFeeMaximum
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Represent minimum annual license fee.

+ References

No definition available.

+ Details

Name:	bcrx_AnnualLicenseFeeMinimum
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Represents collaborative agreement contract maximum amount if all contract options are exercised, to manufacture and evaluate the safety, efficacy and tolerability of galidesivir.

+ References

No definition available.

+ Details

Name:	bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents collaborative agreement contract value.

+ References

No definition available.

+ Details

Name:	bcrx_CollaborativeAgreementContractValue
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Period of time between the contract date and its expiration.

+ References

No definition available.

+ Details

Name:	bcrx_ContractTerm
Namespace Prefix:	bcrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents expected receivable from awards for research and development contracts.

+ References

No definition available.

+ Details

Name:	bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The maximum percentage of customary reductions allowed on royalty rate.

+ References

No definition available.

+ Details

Name:	bcrx_MaximumCustomaryReductionOnRoyaltyRate
Namespace Prefix:	bcrx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Represents milestone payment maximum.

+ References

No definition available.

+ Details

Name:	bcrx_MilestonePaymentMaximum
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents milestone payment minimum.

+ References

No definition available.

+ Details

Name:	bcrx_MilestonePaymentMinimum
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents the amount of milestone payment received.

+ References

No definition available.

+ Details

Name:	bcrx_MilestonePaymentReceived
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents period of agreement.

+ References

No definition available.

+ Details

Name:	bcrx_PeriodOfAgreement
Namespace Prefix:	bcrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents potential milestone payments receivable based on possibility of future event payments.

+ References

No definition available.

+ Details

Name:	bcrx_PotentialMilestonePaymentsReceivable
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The amount of potential milestone payments receivable if regulatory approval is granted before December 31, 2021.

+ References

No definition available.

+ Details

Name:	bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Represents proceeds from awards for research and development contracts.

+ References

No definition available.

+ Details

Name:	bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents renewable period of agreement.

+ References

No definition available.

+ Details

Name:	bcrx_RenewablePeriodOfAgreement
Namespace Prefix:	bcrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The expiration term of the royalty payments from first commercial date.

+ References

No definition available.

+ Details

Name:	bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial
Namespace Prefix:	bcrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The percent of net sales that the company will receive if berotralstat maintains its Sakigake designation during the PMDA review.

+ References

No definition available.

+ Details

Name:	bcrx_RoyaltyRateIfMaintainsSakigakeDesignation
Namespace Prefix:	bcrx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Represents upfront payments receivable.

+ References

No definition available.

+ Details

Name:	bcrx_UpfrontPaymentsReceivableAmount
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349

+ Details

Name:	us-gaap_GainLossRelatedToLitigationSettlement
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount of receivables that are derived from government contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 310
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123371682&loc=d3e55295-109406

+ Details

Name:	us-gaap_GovernmentContractReceivable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

Name:	us-gaap_LegalFees
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount awarded from other party in judgment or settlement of litigation.

+ References

No definition available.

+ Details

Name:	us-gaap_LitigationSettlementAmountAwardedFromOtherParty
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Cash received from licensees for license fees during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	srt_LitigationCaseAxis=bcrx_ArbitrationProceedingsOfSulAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=bcrx_CSLLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: